Expand AKTS Menu
AKTS MENU

AKTS Latest Press Releases

-- May 27, 2026 --

Aktis Oncology to Present at the Jefferies Global Healthcare Conference Globe Newswire 4:05 PM

-- May 21, 2026 --

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors Globe Newswire 5:21 PM

-- May 11, 2026 --

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 Globe Newswire 4:01 PM

-- May 6, 2026 --

Aktis Oncology to Present at the BofA Securities Health Care Conference Globe Newswire 8:00 AM

-- May 4, 2026 --

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Globe Newswire 4:05 PM

-- May 3, 2026 --

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics' Acquisition by UCB Business Wire 8:00 PM

-- April 21, 2026 --

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire 5:00 PM

-- April 16, 2026 --

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors Globe Newswire 8:00 AM

-- March 30, 2026 --

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes